Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › Clovis Oncology's Rubraca Gets FDA Approval for BRCA-Mutated, Difficult-to-Treat Prostate Cancer

Clovis Oncology's Rubraca Gets FDA Approval for BRCA-Mutated, Difficult-to-Treat Prostate Cancer

May 15, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration has approved Clovis Oncology's rucaparib (Rubraca) for men with BRCA1/2-mutated, metastatic castration-resistant prostate cancer who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. UK's NICE Recommends Merck's Keytruda for Head and Neck Cancer With PD-L1 Expression

  2. Allarity Pushes Back NDA Filing for Kidney Cancer Drug to 2021

  3. AstraZeneca's sNDA for Tagrisso in Adjuvant, EGFR-Mutated Lung Cancer Accepted by FDA

  4. Agios Withdraws Tibsovo EU Marketing Application for IDH1-mutated Refractory AML

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.